^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CD5 positive

i
Other names: CD5, CD5 Molecule, T-Cell Surface Glycoprotein CD5, Lymphocyte Antigen T1/Leu-1, CD5 Antigen (P56-62), LEU1, Epididymis Secretory Sperm Binding Protein, CD5 Antigen
Entrez ID:
Related biomarkers:
12ms
Pupil sparing oculomotor nerve palsy with concomitant Horner syndrome as a presentation of mantle cell lymphoma relapse. (PubMed, BMJ Case Rep)
She was treated with intrathecal chemotherapy with improvement in symptoms and resolution of ophthalmoplegia but was left with residual anisocoria and mild ptosis. This presentation (concomitant Horner and ipsilateral ONP) is rare and typically localises to the ipsilateral cavernous sinus, which appeared radiologically normal in this case.
Journal
|
CD5 (CD5 Molecule)
|
CD5 positive
12ms
Primary large B-cell lymphoma of the central nervous system: A reappraisal of CD5-positive cases based on clinical, pathological, and molecular evaluation. (PubMed, Pathol Int)
Indeed, no structural variations or copy number alterations involving PD-1 ligands were detected by targeted-capture sequencing and fluorescence in situ hybridization. While further studies are warranted, we may have confirmed similarity between PCNS-LBCLs and intravascular large B-cell lymphomas from a molecular standpoint.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD79B (CD79b Molecule) • CD5 (CD5 Molecule)
|
PD-L1 expression • MYD88 L265P • CD79B mutation • CD5 positive
1year
Spontaneous tumour lysis syndrome in chronic lymphocytic leukaemia: an unanticipated complication of an undiagnosed disease. (PubMed, BMJ Case Rep)
With prompt diagnosis, intervention and intensive monitoring, the end-organ damage was successfully prevented. This case report highlights the importance of keeping high index of suspicion for STLS even without a background history of malignancy as this life-threatening condition is potentially salvageable.
Journal
|
PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD5 (CD5 Molecule) • CD200 (CD200 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
|
CD20 positive • CD5 positive
1year
Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
P1, N=19, Terminated, Beijing Boren Hospital | Recruiting --> Terminated; ethic commitee decision
Trial termination
|
CD5 (CD5 Molecule)
|
CD5 positive
|
cyclophosphamide
1year
Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma (clinicaltrials.gov)
P1, N=0, Withdrawn, Beijing Boren Hospital | N=18 --> 0 | Trial completion date: Jul 2024 --> Dec 2023 | Recruiting --> Withdrawn | Trial primary completion date: Jul 2024 --> Dec 2023
Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
|
CD5 (CD5 Molecule)
|
CD5 positive
|
cyclophosphamide • CD5 CAR T (CT125B)
1year
Erythema Nodosum Secondary to CD5-Positive Diffuse Large B-Cell Lymphoma as a Paraneoplastic Symptom: A Case Report. (PubMed, Case Rep Oncol)
The lymphoma and EN developed simultaneously and followed a parallel clinical course after chemotherapy, suggesting that EN was a paraneoplastic symptom of CD5+ DLBCL. Recognizing and treating underlying malignancies in patients presenting with EN is crucial.
Journal
|
CD5 (CD5 Molecule)
|
CD5 positive
1year
New P2 trial • Combination therapy
|
CD5 (CD5 Molecule)
|
CD5 positive
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Inokai (orelabrutinib)
1year
Dysregulated MicroRNAs in Chronic Lymphocytic Leukemia. (PubMed, Cureus)
Moreover, the prognostic markers and treatment recommendations based on predictive markers are limited. This review aims to investigate some miRNAs that are dysregulated and possibly involved in CLL pathogenesis as a starting point for the proposal of new prognostic and predictive markers and, as more agents targeting miRNA expression become available, their potential role as therapeutic targets.
Review • Journal
|
CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
|
CD5 positive
1year
An Unusual Case of CD5-Positive Extranodal Marginal Zone Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT) Involving the Appendix. (PubMed, Cureus)
Lymphoma associated with thrombophilia is a rare presentation and not many cases have been reported in the literature. We present this case here on account of the rarity of lymphoma involving the appendix with associated thrombophilia.
Journal
|
CD5 (CD5 Molecule)
|
CD5 positive
over1year
Risk of Incident Melanoma Among Individuals With Low-Count Monoclonal B-Cell Lymphocytosis. (PubMed, J Clin Oncol)
LC-MBL is associated with an approximately two-fold increased risk of melanoma overall and a 2.74-fold increased risk of melanoma in situ.
Journal
|
CD5 (CD5 Molecule)
|
CD5 positive
over1year
Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia (clinicaltrials.gov)
P3, N=202, Completed, University of Ulm | Active, not recruiting --> Completed
Trial completion
|
CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • FCER2 (Fc Fragment Of IgE Receptor II)
|
CD20 positive • CD5 positive
|
Rituxan (rituximab) • bortezomib • cyclophosphamide
over1year
The differential diagnosis of lymphoepithelial lesion of the salivary gland. (PubMed, Semin Diagn Pathol)
Carcinoma showing thymus-like elements has recently been reported in the salivary gland. Similar to thymic carcinoma, tumor cells are positive for CD5 and are accompanied by T lymphocytes.
Review • Journal
|
CD5 (CD5 Molecule)
|
CD5 positive